R&D channel feed – Endpoints News

R&D channel feed

BioNTech, Regeneron claim Phase 2 win for cancer vaccine, PD-1 combo

9 months ago

Celldex says antibody drug improves irritable skin condition in Phase 2 test

9 months ago

Roche begins Phase 2 obesity trial for GLP-1/GIP agonist, striking while iron is hot

9 months ago

Ventyx axes development of TYK2 inhibitor following Phase 2 failure

9 months ago

Cognition Therapeutics' stock sinks on Phase 2 Alzheimer’s data

9 months ago

NewAmsterdam succeeds in the first of three key pivotal studies, providing hope to a troubled cardio class

9 months ago

AstraZeneca’s fixed-duration Calquence combo succeeds in Phase 3 blood cancer test

9 months ago

vTv Therapeutics' diabetes drug program hit with clinical hold from FDA

9 months ago

Anavex’s new analysis of its Alzheimer’s pill shows mixed results

9 months ago

Updated: Bristol Myers restarts radiopharmaceutical Phase 3 trial

9 months ago

Cue Biopharma prioritizes autoimmune pipeline, axes a quarter of staff to save cash

9 months ago

Calliditas claims mid-stage win for rare liver disease drug

9 months ago

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

9 months ago

FDA advisors call for better studies of immunotherapy around lung cancer surgery, but give AstraZeneca a pass

9 months ago

Sanofi shelves four assets, including mid-stage dwarfism candidate

9 months ago

AbbVie expects $8.7B Cerevel buy to close ‘as early as next week,’ new CEO says

9 months ago

Roche cuts two more TIGIT trials, plans accelerated timeline for obesity drugs

9 months ago

Argenx to retest Vyvgart in autoimmune platelet disease after failure last year

9 months ago

Viking to push obesity drug to Phase 3 in bid to reach market faster

9 months ago

Pfizer touts Phase 3 gene therapy data in hemophilia A, but now it needs to prove it can win the market

9 months ago

Sage's essential tremor drug fails in another blow to pipeline, Biogen partnership

9 months ago

Exclusive: RA Capital invests $35M in UK cancer biotech CellCentric

9 months ago

AstraZeneca signs preclinical EGFR drug deal with antibody biotech

9 months ago

What's changed about rare disease medicine

9 months ago

First page Previous page 32 33 343536 37 38 Next page Last page